8-K: ImmunityBio Reports 700% Revenue Growth, Global ANKTIVA Wins

ImmunityBio, Inc. announced preliminary Q4 and full-year 2025 financial results, highlighting a 700% year-over-year increase in ANKTIVA net product revenue and new global approvals.

Summary

• Preliminary net product revenue for the full year ending December 31, 2025, was approximately $113.0 million, representing a ~700% increase year-over-year.
• Preliminary net product revenue for the three-month period ending December 31, 2025, was approximately $38.3 million.
• This Q4 2025 revenue marks a 20% increase over the $31.8 million reported in the prior quarter (Q3 2025) and a 431% increase over the three-month period ended December 31, 2024.
• ANKTIVA unit sales volume grew 750% in 2025 compared to 2024, with a 54% quarter-over-quarter unit volume growth rate during FY 2025.
• The company ended the quarter with an estimated $242.8 million in cash, cash equivalents, and marketable securities as of December 31, 2025.
• The Saudi FDA (SFDA) granted approval of ANKTIVA in combination with immune checkpoint inhibitors for adults with metastatic non-small cell lung cancer (NSCLC) who have failed standard therapies, marking the first global approval for this indication and the first approval of ANKTIVA for subcutaneous administration.
• The SFDA also approved ANKTIVA in combination with BCG for patients with BCG-unresponsive non-muscle invasive bladder cancer carcinoma in situ (NMIBC CIS), adding to existing approvals in the U.S. and U.K., and conditional approval in the European Union.
• Enrollment in the ongoing Phase 2b QUILT-2.005 trial evaluating ANKTIVA plus intravesical BCG in first-line, BCG-naive NMIBC is progressing ahead of internal expectations, with full enrollment anticipated in the first half of 2026.

Sentiment

Score: 9

Explanation: The company reported exceptionally strong preliminary financial results with significant year-over-year and quarter-over-quarter revenue growth for ANKTIVA, coupled with substantial unit sales volume increases. Key regulatory approvals in Saudi Arabia for new indications and administration methods further expand market opportunities and validate the company's platform. Clinical trial enrollment is also ahead of schedule, indicating positive operational momentum. The strong cash position provides financial stability.

Positives

• Full year 2025 preliminary net product revenue of approximately $113.0 million, a ~700% increase year-over-year, demonstrates strong commercial execution.
• Q4 2025 preliminary net product revenue of approximately $38.3 million, a 20% quarter-over-quarter increase and 431% increase over Q4 2024, indicates accelerating sales momentum.
• ANKTIVA unit sales volume grew 750% in 2025 compared to 2024, reflecting robust market adoption.
• Saudi FDA approval of ANKTIVA for metastatic NSCLC marks the first global approval for this indication and the first for subcutaneous administration, expanding market reach and treatment options.
• Saudi FDA approval of ANKTIVA for BCG-unresponsive NMIBC CIS further strengthens the product's international presence and addresses an unmet medical need.
• Enrollment in the Phase 2b QUILT-2.005 trial for NMIBC is progressing ahead of internal expectations, suggesting positive clinical development momentum.
• The company maintains a strong cash position with an estimated $242.8 million in cash, cash equivalents, and marketable securities as of December 31, 2025.

Risks

• Preliminary financial estimates may differ materially from actual results reported in the Annual Report on Form 10-K due to financial closing procedures and final adjustments.
• Forward-looking statements involve substantial risks and uncertainties that could cause clinical development programs, commercial success, manufacturing capabilities, and future results to differ significantly.
• Risks include uncertainties regarding participation, enrollment, and potential results from clinical trials.
• Uncertainty exists whether clinical trials will result in registrational pathways or if clinical trial data will be accepted by regulatory agencies.
• The ability to fund ongoing and anticipated clinical trials is a risk factor.
• The ability to continue planned preclinical and clinical development, patient enrollment, and planned regulatory submissions is subject to risks.
• Potential delays in product availability and regulatory approvals could impact the business.
• The ability to retain and hire key personnel is crucial for continued operations.
• The ability to obtain additional financing to fund operations and complete development and commercialization of product candidates is a risk.
• Potential product shortages or manufacturing disruptions may impact product availability and timing.
• The ability to successfully commercialize approved products and product candidates is not guaranteed.
• The ability to scale manufacturing and commercial supply operations for approved and future products is a challenge.
• The ability to obtain, maintain, protect, and enforce patent protection and other proprietary rights for product candidates and technologies is essential.

Future Outlook

ImmunityBio anticipates sustained growth, aiming to redefine the standard of care across multiple cancers through its platform strength and continued advancement of its NMIBC program. Full enrollment in the Phase 2b QUILT-2.005 trial is expected in the first half of 2026. The company expects increased sales momentum to continue.

Management Comments

• "We delivered strong quarter-over-quarter revenue growth, reflecting accelerating adoption of ANKTIVA and the continued execution of our commercial strategy." Richard Adcock, President and CEO.
• "This momentum is further reinforced by the approval of ANKTIVA plus BCG in Saudi Arabia, building on existing approvals in the U.S. and U.K, as well as conditional approval in the EU." Richard Adcock, President and CEO.
• "The SFDAs landmark approval of ANKTIVA in combination with a checkpoint inhibitor for non-small cell lung cancer marks the worlds first approval of an IL-15 superagonist used in combination with checkpoint therapy." Patrick Soon-Shiong, M.D., Founder, Executive Chairman and Global Chief Scientific and Medical Officer.
• "This approval also represents the first authorization for subcutaneous administration of ANKTIVA. Together with the continued advancement of our first-line NMIBC program, these milestones underscore the strength of our platform and position ImmunityBio for sustained growth as we work to redefine the standard of care across multiple cancers." Patrick Soon-Shiong, M.D.

Industry Context

The approvals of ANKTIVA, particularly for NSCLC in combination with checkpoint inhibitors and for subcutaneous administration, position ImmunityBio as a leader in developing next-generation immunotherapies. The focus on activating NK cells, T cells, and memory T cells for durable responses aligns with broader industry trends towards leveraging the body's own immune system to combat cancer, potentially offering more effective and accessible treatments than traditional high-dose chemotherapy. The expansion into global markets like Saudi Arabia also indicates a growing international recognition and demand for innovative cancer treatments.

Comparison to Industry Standards

• ANKTIVA's approval as the world's first IL-15 superagonist used in combination with checkpoint therapy for NSCLC sets a new benchmark in this specific treatment modality, differentiating it from existing checkpoint inhibitor monotherapies or other combination approaches.
• The approval for subcutaneous administration of ANKTIVA offers a more convenient and potentially more accessible treatment option compared to intravenous administration, which is common for many existing cancer immunotherapies.
• The 700% year-over-year revenue growth and 750% unit sales volume growth for ANKTIVA significantly outperform typical growth rates for established pharmaceutical products, indicating strong market adoption for a relatively new therapy in its approved indications.

Stakeholder Impact

• Shareholders: Positive impact due to strong revenue growth, expanding market approvals, and clinical trial progress, potentially leading to increased share value.
• Patients: Expanded access to ANKTIVA for new indications (metastatic NSCLC, NMIBC CIS) and a more convenient subcutaneous administration method.
• Employees: Positive outlook due to company growth and commercial success, potentially leading to job security and expansion.

Next Steps

• Finalization and public disclosure of actual amounts in the Annual Report on Form 10-K for the year ended December 31, 2025.
• Continued enrollment in the Phase 2b QUILT-2.005 trial, with full enrollment anticipated in the first half of 2026.
• Further execution of commercial strategy for ANKTIVA.
• Application of science and platforms to treat cancers and develop immunotherapies and cell therapies.

Key Dates

Recommendation

The filing details exceptional preliminary financial performance with a 700% year-over-year revenue increase and substantial quarter-over-quarter growth for ANKTIVA. The significant unit sales volume growth indicates strong market adoption. Crucially, the landmark global approvals in Saudi Arabia for metastatic NSCLC (first IL-15 superagonist with checkpoint inhibitor, first subcutaneous administration) and NMIBC CIS open new, substantial market opportunities and validate the company's innovative platform. Clinical trial progress ahead of expectations further de-risks future pipeline. Combined with a healthy cash position, these factors suggest strong future growth potential and a compelling investment case.

Keywords

ImmunityBio, IBRX, ANKTIVA, Biotechnology, Oncology, Cancer Therapy, NMIBC, NSCLC, FDA Approval, Financial Results, Revenue Growth, Clinical Trials, Immunotherapy, Pharmaceuticals